| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Kronos Bio, Inc. | COO & General Counsel | Common Stock | 929K | $1.1M | $1.18 | Jan 4, 2024 | Direct |
| PHOENIX BIOTECH ACQUISITION CORP. | Director | Class A Common Stock | 5.83K | $58.3K | $10.00 | Feb 14, 2024 | Direct |
| Kronos Bio, Inc. | COO & General Counsel | Employee Stock Option (Right to Buy) | 208K | Feb 15, 2023 | Direct | ||
| Athira Pharma, Inc. | Director | Stock Option (Right to Buy) | 20.9K | May 24, 2024 | Direct | ||
| XOMA Corp | Director | Non-Qualified Share Option (right to buy) | 9.76K | May 15, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ATHA | Athira Pharma, Inc. | May 24, 2024 | 1 | $0 | 4 | May 24, 2024 | Director |
| XOMA | XOMA Corp | May 15, 2024 | 1 | $0 | 4 | May 17, 2024 | Director |
| CERO | PHOENIX BIOTECH ACQUISITION CORP. | Feb 14, 2024 | 1 | $0 | 4 | Feb 16, 2024 | Director |
| KRON | Kronos Bio, Inc. | Jan 4, 2024 | 1 | -$12.6K | 4 | Jan 5, 2024 | COO & General Counsel |
| ATHA | Athira Pharma, Inc. | May 19, 2023 | 1 | $0 | 4 | May 22, 2023 | Director |
| XOMA | XOMA Corp | May 17, 2023 | 1 | $0 | 4 | May 19, 2023 | Director |
| KRON | Kronos Bio, Inc. | Feb 15, 2023 | 2 | $0 | 4 | Feb 17, 2023 | COO & General Counsel |
| KRON | Kronos Bio, Inc. | Jul 25, 2022 | 1 | $0 | 4 | Jul 27, 2022 | COO & General Counsel |
| ATHA | Athira Pharma, Inc. | May 20, 2022 | 1 | $0 | 4 | May 27, 2022 | Director |
| XOMA | XOMA Corp | May 18, 2022 | 1 | $0 | 4 | May 20, 2022 | Director |
| KRON | Kronos Bio, Inc. | Feb 15, 2022 | 2 | $0 | 4 | Feb 17, 2022 | COO & General Counsel |
| PBAX | PHOENIX BIOTECH ACQUISITION CORP. | Oct 8, 2021 | 1 | $0 | 4 | Oct 12, 2021 | Director |
| PBAX | PHOENIX BIOTECH ACQUISITION CORP. | Oct 5, 2021 | 0 | $0 | 3 | Oct 5, 2021 | Director |
| XOMA | XOMA Corp | May 19, 2021 | 1 | $0 | 4 | May 21, 2021 | Director |